Yuan T, Bi F, Hu K, Zhu Y, Lin Y, Yang J
Clin Pharmacokinet. 2024; 63(8):1147-1165.
PMID: 39102093
DOI: 10.1007/s40262-024-01404-0.
Avan A
Turk J Chem. 2023; 46(6):2024-2035.
PMID: 37621342
PMC: 10446920.
DOI: 10.55730/1300-0527.3499.
Mansoor K, Bardees R, Alkhawaja B, Mallah E, Abuqatouseh L, Schmidt M
Molecules. 2023; 28(5).
PMID: 36903363
PMC: 10003857.
DOI: 10.3390/molecules28052117.
Marie S, Frost K, Hau R, Martinez-Guerrero L, Izu J, Myers C
Acta Pharm Sin B. 2023; 13(1):1-28.
PMID: 36815037
PMC: 9939324.
DOI: 10.1016/j.apsb.2022.08.018.
Wu S, Hoang H, Yang J, Papamatheakis D, Poch D, Alotaibi M
Chest. 2022; 162(6):1360-1372.
PMID: 35841932
PMC: 9773230.
DOI: 10.1016/j.chest.2022.06.042.
Sildenafil 4.0-Integrated Synthetic Chemistry, Formulation and Analytical Strategies Effecting Immense Therapeutic and Societal Impact in the Fourth Industrial Era.
Ouranidis A, Tsiaxerli A, Vardaka E, Markopoulou C, Zacharis C, Nicolaou I
Pharmaceuticals (Basel). 2021; 14(4).
PMID: 33920975
PMC: 8071249.
DOI: 10.3390/ph14040365.
Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants.
Salerno S, Edginton A, Gerhart J, Laughon M, Ambalavanan N, Sokol G
Clin Pharmacol Ther. 2020; 109(1):253-262.
PMID: 32691891
PMC: 8138939.
DOI: 10.1002/cpt.1990.
Species differences in the CYP3A-catalyzed metabolism of TPN729, a novel PDE5 inhibitor.
Tian Q, Zhu Y, Diao X, Zhang X, Xu Y, Jiang X
Acta Pharmacol Sin. 2020; 42(3):482-490.
PMID: 32581257
PMC: 8027186.
DOI: 10.1038/s41401-020-0447-x.
Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects.
Lv Y, Luo B, LaBadie R, Zhu H, Feng Y, Ernst C
Clin Pharmacol Drug Dev. 2020; 9(5):573-581.
PMID: 32463593
PMC: 7384059.
DOI: 10.1002/cpdd.806.
Population pharmacokinetics of sildenafil in extremely premature infants.
Gonzalez D, Laughon M, Smith P, Ge S, Ambalavanan N, Atz A
Br J Clin Pharmacol. 2019; 85(12):2824-2837.
PMID: 31475367
PMC: 6955411.
DOI: 10.1111/bcp.14111.
Update of green tea interactions with cardiovascular drugs and putative mechanisms.
Werba J, Misaka S, Giroli M, Shimomura K, Amato M, Simonelli N
J Food Drug Anal. 2018; 26(2S):S72-S77.
PMID: 29703388
PMC: 9326886.
DOI: 10.1016/j.jfda.2018.01.008.
An opportunistic study evaluating pharmacokinetics of sildenafil for the treatment of pulmonary hypertension in infants.
Thakkar N, Gonzalez D, Cohen-Wolkowiez M, Massaro M, Bernhardt J, Zane N
J Perinatol. 2016; 36(9):744-7.
PMID: 27171763
PMC: 5002251.
DOI: 10.1038/jp.2016.79.
Antioxidant Potential and Ability of Phloroglucinol to Decrease Formation of Advanced Glycation End Products Increase Efficacy of Sildenafil in Diabetes-Induced Sexual Dysfunction of Rats.
Goswami S, Gangadarappa S, Vishwanath M, Razdan R, Jamwal R, Bhadri N
Sex Med. 2016; 4(2):e104-12.
PMID: 26831914
PMC: 5005294.
DOI: 10.1016/j.esxm.2015.12.002.
Pharmacokinetic interaction between Kaempferia parviflora extract and sildenafil in rats.
Mekjaruskul C, Sripanidkulchai B
J Nat Med. 2015; 69(2):224-31.
PMID: 25567192
DOI: 10.1007/s11418-014-0882-4.
Safety of sildenafil in infants*.
Samiee-Zafarghandy S, Smith P, van den Anker J
Pediatr Crit Care Med. 2014; 15(4):362-8.
PMID: 24583505
PMC: 4709254.
DOI: 10.1097/PCC.0000000000000077.
Priapism, pomegranate juice, and sildenafil: Is there a connection?.
Senthilkumaran S, Balamurugan N, Suresh P, Thirumalaikolundusubramanian P
Urol Ann. 2012; 4(2):108-10.
PMID: 22629009
PMC: 3355694.
DOI: 10.4103/0974-7796.95560.
Roles of sildenafil in enhancing drug sensitivity in cancer.
Shi Z, Tiwari A, Patel A, Fu L, Chen Z
Cancer Res. 2011; 71(11):3735-8.
PMID: 21610107
PMC: 3107342.
DOI: 10.1158/0008-5472.CAN-11-0375.
Substrate-specific pharmacokinetic interaction between endothelin receptor antagonists and phosphodiesterase-5 inhibitors--assembling the clues.
Srinivas N
Br J Clin Pharmacol. 2009; 67(4):475-7.
PMID: 19371324
PMC: 2679114.
DOI: 10.1111/j.1365-2125.2009.03374.x.
Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study.
Sekar V, Lefebvre E, De Marez T, De Pauw M, De Paepe E, Vangeneugden T
Clin Drug Investig. 2008; 28(8):479-85.
PMID: 18598093
DOI: 10.2165/00044011-200828080-00002.
Sildenafil: a review of its use in pulmonary arterial hypertension.
Croom K, Curran M
Drugs. 2008; 68(3):383-97.
PMID: 18257613
DOI: 10.2165/00003495-200868030-00009.